Overview

Liposomal Bupivacaine After Arthroscopic Rotator Cuff Repair

Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
0
Participant gender:
All
Summary
Liposomal bupivacaine, a long-acting form of bupivacaine, has been found to be effective for postoperative pain control after total knee, total hip and total shoulder arthroplasty. We are conducting a randomized, controlled trial to evaluate pain control after arthroscopic rotator cuff repair in ambulatory patients, comparing standard care in the control group, with standard care plus the addition of injection of liposomal bupivacaine in the experimental group.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Steven Orebaugh
University of Pittsburgh
Collaborator:
Pacira Pharmaceuticals, Inc
Treatments:
Bupivacaine
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- Adult patients up to age 65 years, undergoing elective, ambulatory, arthroscopic
rotator cuff repair.

Exclusion Criteria:

- Pregnancy, coagulopathy, allergy to bupivacaine, renal failure, hepatic insufficiency,
and/or inappropriate candidate for usual therapy (specifically, if unable to receive
the usual preoperative interscalene nerve block: preexisting nerve injury on side of
surgery, refusal of nerve block, infection at site of nerve block).